Jun G Zhang, 42Annandale, VA

6495520, Dec 17, 2002

Feb 19, 1999

09/252656

Reinhard Ebner - Gaithersburg MD
Guo-Liang Yu - Berkeley CA
Steven M. Ruben - Olney MD
Jun Zhang - Bethesda MD
Stephen Ullrich - Rockville MD
Yifan Zhai - Gaithersburg MD

Human Genome Sciences, Inc. - Rockville MD

A61K 3818

514 12, 530300, 530324, 530350

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

6683894, Jan 27, 2004

Apr 19, 2000

09/552579

Hyo Sang Lee - Silver Spring MD
Coorg R. Prasad - Silver Spring MD
Jun Zhang - Ellicott City MD

Science Engineering Services, Inc. - Burtonsville MD

H01S 310

372 20, 372 21, 372 22, 372 10, 372 30, 372101, 372105

A diode pumped solid state laser/OPO system widely tunable in mid infrared spectrum for infrared matrix assisted laser desorption/ionization (MALDI) mass spectroscopy is disclosed. Up to a few tens of milli-Joule, short pulse, tunable near infrared laser pulse is generated from an all solid state laser at a high pulse repetition rate up to one kHz. The tunable near-infrared laser pumps a Quasi-Phase Matching (QPM) OPO system to further shift the wavelength to the mid-IR range and to broaden the tuning range to as much as 3 m to effectively generate a widely tunable spectral output. The wide range tuning of the infrared output is accomplished by a narrow range tuning of the pump laser. The pump laser output is generated by a diode pumped tunable solid state laser module using either a Yb:YAG crystal or any other efficient tunable laser crystals. The wavelength range (2-5 m) covered by the solid state laser system is optimum for MALDI applications. This wavelength range is especially beneficial for large mass DNA analysis.

6693077, Feb 17, 2004

Jun 30, 2000

09/610651

Steven M. Ruben - Brookeville MD
Pablo Jimenez - Chatham NJ
D. Roxanne Duan - Gaithersburg MD
Mark A. Rampy - Montgomery Village MD
Donna Mendrick - Mount Airy MD
Jun Zhang - San Diego CA
Jian NI - Germantown MD
Paul A. Moore - North Bethesda MD
Timothy A. Coleman - Gaithersburg MD
Joachim R. Gruber - Dallas TX
Patrick J. Dillon - Carlsbad CA
Reiner L. Gentz - Belo Horizonte-Mg, BR

Human Genome Sciences, Inc. - Rockville MD

A61K 3818

514 12, 514 2, 530399

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as âKGF-2â also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

6811773, Nov 2, 2004

May 15, 2000

09/571013

Reiner L. Gentz - Silver Spring MD
Brent L. Kreider - Germantown MD
Jun Zhang - Bethesda MD
Michael Antonaccio - Germantown MD
Donna Mendrick - Mt. Airy MD
Pablo Jimenez - Ellicott City MD
Vikram Patel - Germantown MD
Craig A. Rosen - Laytonsville MD
Mark D. Adams - North Potomac MD
Haodong Li - Gaithersburg MD
Steven M. Ruben - Olney MD

Human Genome Sciences, Inc. - Rockville MD

A61K 3819

424 851, 530324, 514 2, 514 8, 514 12, 536 235, 435 695, 435 697, 435 711, 435 712, 435471, 4352523, 43525411, 4353201

There are disclosed therapeutic compositions and methods using a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1- chemokine 1(CK1 or ckb-1)), as well as ioslated nucleic acid molecules encoding M-CIF, and vectors, host cells and recombinant methods for producing the same.

6903072, Jun 7, 2005

Jul 1, 1999

09/345373

Steven M. Ruben - Olney MD, US
Pablo Jimenez - Ellicott City MD, US
D. Roxanne Duan - Bethesda MD, US
Mark A. Rampy - Gaithersburg MD, US
Donna Mendrick - Mt. Airy MD, US
Jun Zhang - Bethesda MD, US
Jian Ni - Rockville MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Joachim R. Gruber - Chestnut Hill MA, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Rockville MD, US

Human Genome Sciences, Inc. - Rockville MD

A61K038/18
C07K014/50
C12N015/18
C12N001/21

514 12, 514 2, 530399, 530402, 435 694, 435 697, 435243

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

6916786, Jul 12, 2005

Feb 15, 2002

10/075446

Steven M. Ruben - Olney MD, US
Pablo Jimenez - Ellicot City MD, US
D. Roxanne Duan - Bethesda MD, US
Mark A. Rampy - Montgomery Village MD, US
Donna Mendrick - Mount Airy MD, US
Jun Zhang - Bethesda MD, US
Jian Ni - Rockville MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Joachim R. Gruber - Dallas TX, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Rockville MD, US

Human Genome Sciences, Inc. - Rockville MD

A61K038/18
C07K014/50
C12N001/20
C12N005/10

514 12, 530399, 435 694, 435 697, 435243

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

7232667, Jun 19, 2007

Dec 12, 2003

10/733311

Steven M. Ruben - Brookeville MD, US
Joachim R. Gruber - Dallas TX, US
D. Roxanne Duan - Gaithersburg MD, US
Mark A. Rampy - Montgomery Village MD, US
Donna Mendrick - Mount Airy MD, US
Jun Zhang - San Diego CA, US
Jian Ni - Germantown MD, US
Paul A. Moore - Germantown MD, US
Timothy A. Coleman - Gaithersburg MD, US
Patrick J. Dillon - Carlsbad CA, US
Reiner L. Gentz - Belo Horizonte-Mg, BR
Pablo Jimenez - Chatham NJ, US

Human Genome Sciences, Inc. - Rockville MD

C12N 1/21
C12N 5/10
C12N 15/12
C12N 15/63
C07K 14/50

435 694, 435 697, 435325, 435243, 4353201, 536 234, 536 2351, 530399

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.

2003004, Mar 13, 2003

Dec 27, 2001

10/033741

Eugene Herman - Takoma Park MD, US
Gordon Holt - Gaithersburg MD, US
Frank Sistare - Ellicott City MD, US
Jun Zhang - Rockville MD, US

C12Q001/68
G01N033/53
G01N033/542
G01N033/557

435/006000, 435/007900, 436/517000

The present invention provides methods and compositions for screening, diagnosis and prognosis of vascular response, for monitoring the effectiveness of vascular response treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. In particular, the screening of drug candidates for their ability to induce a vascular response. Vascular Response-Associated Features (VRFs), detectable by two-dimensional electrophoresis of blood, serum or plasma are described. The invention further provides Vascular Response-Associated Protein Isoforms (VRPIs) detectable in blood, serum or plasma, preparations comprising isolated VRPIs, antibodies immunospecific for VRPIs, and kits comprising the aforesaid.